LSV Asset Management Purchases 36,700 Shares of BioMarin Pharmaceutical Inc. $BMRN

LSV Asset Management lifted its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 882,200 shares of the biotechnology company’s stock after acquiring an additional 36,700 shares during the quarter. LSV Asset Management’s holdings in BioMarin Pharmaceutical were worth $52,429,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Viking Global Investors LP grew its stake in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of BioMarin Pharmaceutical by 6.3% in the 3rd quarter. AQR Capital Management LLC now owns 5,932,109 shares of the biotechnology company’s stock worth $321,283,000 after acquiring an additional 351,536 shares in the last quarter. Capital Research Global Investors grew its stake in shares of BioMarin Pharmaceutical by 547.5% in the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock worth $137,436,000 after acquiring an additional 2,145,717 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of BioMarin Pharmaceutical by 42.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,245,186 shares of the biotechnology company’s stock worth $121,597,000 after acquiring an additional 671,566 shares in the last quarter. Finally, Northern Trust Corp grew its stake in shares of BioMarin Pharmaceutical by 0.4% in the 3rd quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock worth $90,028,000 after acquiring an additional 7,157 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN opened at $54.09 on Monday. The firm has a market cap of $10.45 billion, a P/E ratio of 39.48, a PEG ratio of 0.41 and a beta of 0.23. The firm has a 50-day moving average of $54.56 and a 200 day moving average of $56.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.20 and a current ratio of 5.81. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $66.28.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Citigroup started coverage on shares of BioMarin Pharmaceutical in a research note on Tuesday, May 19th. They issued a “buy” rating and a $75.00 target price for the company. Wolfe Research restated an “outperform” rating on shares of BioMarin Pharmaceutical in a research report on Monday, March 16th. Wells Fargo & Company increased their price target on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Truist Financial upgraded shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Oppenheimer reduced their price target on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Tuesday, February 24th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $88.67.

Insider Activity

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president owned 79,953 shares in the company, valued at $4,833,958.38. This trade represents a 17.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 26,093 shares of company stock valued at $1,555,389. 0.85% of the stock is owned by company insiders.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.